Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Special Projects for Equitable and Efficient Distribution (SPEED) of COVID-19 Outpatient Therapeutics

The Special Projects for Equitable and Efficient Distribution (SPEED) program is focused on increasing the availability of COVID-19 outpatient therapeutics (monoclonal antibody therapeutics [mAbs]) to vulnerable and underserved populations. Prioritizing long-term care facilities (LTCF), dialysis centers, federally qualified health centers (FQHCs), and correctional facilities, SPEED helps interested sites assess their readiness to administer mAbs.

Monoclonal antibody treatments, which are available under FDA’s Emergency Use Authorization, have been shown to reduce hospitalization and symptom days in certain adult and pediatric high-risk COVID-19 positive individuals with mild to moderate symptoms.  Your eligible patients who have had mild to moderate symptoms for 10 days or less may benefit from treatment with certain monoclonal antibody drugs.


Getting mAbs to underserved communities

SPEED began as a program to allocate and distribute mAbs to underserved communities during the time that monoclonal antibody therapeutics were available through allocation. SPEED formed partnerships with leaders and professional organizations associated with each of the provider types to help get mAbs to people in those communities more quickly.

In just a few months, SPEED had allocated nearly 30,000 patient courses to almost 1,000 priority settings across 49 states. To accomplish this, SPEED worked with 24 FQHCs representing more than 350 sites, over 1,000 dialysis centers, 172 home infusion providers 521 long-term care pharmacies, and 80 correctional facilities.

Now that allocation has ended, providers can work through the direct order process, so SPEED is no longer playing a role in directly allocating products to facilities in underserved communities. 


Continuing to Partner to Expand mAb Access

In the battle against COVID-19, SPEED will continue to champion equitable access and utilization of mAbs, including the continuation of engagements with existing partners and sites, identification of new partners that represent other vulnerable and underserved populations, collaboration with other Federal partners, and work with the COVID-19 Health Equity Task Force.

There are many factors to consider when choosing to administer mAbs. If your site is interested in administering these products to improve the health of the communities you serve, select your individual facility type to learn about planning considerations, ordering, tracking, seeking reimbursement, and more. You can also reach out to SPEED partners in the professional associations you partner with on a regular basis.


Long Term Care Facilities icon

Long-term Care Facilities (LTCF)

  • National Home Infusion Association (NHIA)
  • American Society of Consultant Pharmacists (ASCP)
  • Society for Post-Acute and Long-Term Care Medicine (AMDA)
IV icon

Dialysis Centers

Medical symbol icon


Federally Qualified Health Centers

  • National Association of Community Health Centers (NACHC)
  • Emergency Management Advisory Coalition (EMAC)
  • HRSA Bureau of Primary Care (HRSA)
  • Your state’s department of health or primary care association
Government building icon

   Correctional Facilities

  • American Correctional Association (ACA)
  • National Institute of Corrections (NIC)
  • National Commission on Correctional Healthcare (NCCHC)


Three Ways to Connect

 Archived Webinars

Office Hours

Email Us

To learn about clinical models, check out the
COVID-19 Outpatient Therapeutics
Mini Series
.
Sign up for a biweekly meeting on
mAb administration.  For event details,
contact ASPRstakeholder@hhs.gov
If you have questions on getting
started or becoming a SPEED partner,
email us at covidtx@hhs.gov.

  • This page last reviewed: April 12, 2021